Where Syntekabio Sees the Industry Heading
Drug discovery using AI and big data is no longer an experimental attempt.
From hit identification and optimization to toxicity and metabolism prediction,
AI is already reducing time and costs while improving the probability of success.
Around the world, numerous AI-driven biotech startups have emerged, each competing with unique algorithms and strengths.
Syntekabio views the flow of AI drug discovery—expanding from synthetics to vaccines and antibodies—as follows.
Comparing Global AI Drug Discovery Platforms
Among companies that have publicly detailed their discovery approaches are Schrödinger, Insilico Medicine, and Atomwise.
Schrödinger excels in precision Me-Too drug design with its molecular dynamics–based binding affinity calculation platform, FEP+.
Insilico Medicine operates Chemistry42,
a generative AI platform that designs novel structures using multiple models and links them to robotic experimental validation.
Atomwise is known for AtomNet PoseRanker (ANPR),
but due to limited physics-based false-positive elimination, its validation efficiency can be relatively low.
While these services are innovative, they remain extremely costly,
making them less accessible to smaller pharmaceutical companies and research institutes in Korea.
With STB CLOUD, Syntekabio enables the screening of 1 billion compounds in a single click,
followed by pose generation and molecular dynamics (MD) verification to eliminate false positives.
This process ultimately delivers 100–200 AI-Hit candidates.
The strength of STB CLOUD lies in its cloud-based, fully automated environment,
which allows any researcher to rapidly build a pipeline regardless of infrastructure or expertise.
The Key to Higher Hit Discovery Success
The essence of hit discovery is how effectively false positives are minimized.
In silico discovery requires three sequential steps:
Candidate search
Pose generation
Molecular dynamics verification
Because experimental validation is both costly and time-consuming,
it is critical that only highly reliable candidates remain after computational screening.
Both internal studies and published literature show that including MD verification can more than double performance.
Currently, only Syntekabio and Schrödinger have the ability to automatically execute all three steps.
Expanding to Lead Optimization
Securing hits is not enough—lead optimization must follow.
Syntekabio addresses this with its proprietary Gap2 software, which automates lead optimization (Auto-Lead-Optimization).
Gap2 substitutes more than 20,000 R-groups into the binding pocket scaffold and selects optimal structures based on binding energy.
This approach is more efficient than traditional graphics-based methods and enables both novelty and improved activity.
From Small Molecules to Vaccines and Antibodies
Because DeepMatcher® provides detailed binding residue information within the pocket,
it naturally extends beyond small-molecule drugs to vaccines and antibodies.
NEO-ARS™ – AI vaccine platform predicting tumor-specific neoantigens
AB-scan – Antibody optimization platform based on antigen–antibody interactions
The same three-step logic (search, pose generation, MD verification) validated in
small-molecule discovery applies equally to vaccines and antibodies.
This not only shortens development timelines but also enhances scalability across markets.
Syntekabio’s Next Steps
Currently, DeepMatcher® runs continuously for three weeks on more than 200 servers within STB CLOUD,
executing candidate search, pose generation, and MD verification.
Syntekabio is now integrating cutting-edge hardware and large language model (LLM)-based search methods to further enhance performance.
Going forward, Syntekabio plans to sequentially integrate additional platforms
—covering synthetics, vaccines, antibodies, and genome-based solutions—
into STB CLOUD, evolving into a comprehensive partner for end-to-end drug discovery.
✅ In Summary
The key to successful hit discovery is minimizing false positives.
DeepMatcher® automates candidate search, pose generation, and MD verification, ensuring high reliability.
With Gap2-based automated lead optimization, the process extends seamlessly into the lead stage.
The same logic applies to vaccines and antibodies, securing the scalability of the platform.
AI-driven drug discovery is no longer limited to small molecules—it is expanding into vaccines and antibodies.
Building on DeepMatcher® and STB CLOUD, Syntekabio is creating a faster, more reliable environment for next-generation drug development.
🔗 Open Link
[Feature] Syntekabio Draws the Future of “AI Drug Discovery Pipeline & Drug Repurposing” <1>
